Navigation Links
CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
Date:11/14/2011

SAN FRANCISCO, Nov. 14, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented preclinical research results at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in San Francisco, California demonstrating that analogs of novel FAK inhibitor CFAK-C4 disrupted FAK-vascular endothelial growth factor receptor 3 (FAK-VEGFR3) interaction and inhibited pancreatic cancer tumor growth at low concentrations as single agents. The research was conducted by CureFAKtor scientists at the Roswell Park Cancer Institute in Buffalo, New York.

In the poster presentation, Development of Novel FAK Inhibitors Targeting the FAK-VEGFR3 Protein-Protein Interaction Site, CureFAKtor Chief Scientific Officer Dr. William Cance and Senior Scientist Dr. Elena Kurenova reported that oral small molecule FAK inhibitor C4 analogs, C9, C10 and C9A, administered as low dose single agents led to 40 to 60 percent reduction in pancreatic tumor growth in vivo after 30 days of treatment in mouse models. The C4 analogs displayed enhanced potency, minimum toxicity and high specificity for the target site. Abstract C124 will be presented on Tuesday, November 15 from 12:30 to 2:30 pm at West Hall, Level One, Moscone Center West.

"These preclinical results of C4 analogs inhibiting pancreatic tumor growth are very promising and add to our existing C4 data," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals. "We know that FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies."

CureFAKtor Pharmaceuticals recently presented preclinical research results at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain demonstrating that FAK inhi
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
3. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
4. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)...   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue ... media and a related cloud hosted biologistics ... shippers ("BioLife" or the "Company"), today announced ... company focused on developing and commercializing novel therapeutics ...
(Date:8/28/2015)... JACKSONVILLE, Fla. , Aug. 28, 2015  With ... reaching deadlier heights, Jacksonville ... Philip Hemphill is helping to explain why ... Fentanyl is approximately 40 to 50 times more potent ... by recreational users as heroin, the risk of death ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
(Date:8/31/2015)... ... September 01, 2015 , ... The PT Outcomes Registry is an organized ... physical therapy patients. The Registry is being developed by the American Physical Therapy Association ... happy to be selected to contribute FOTO Outcomes measures as one of the primary ...
(Date:8/31/2015)... ... August 31, 2015 , ... ITC Global Translations website, ... for specific translation services within the medical and pharmaceutical industries. These are industries ... successful work. , ITC Global Translations specializes in professional translation services for materials ...
(Date:8/31/2015)... Florida (PRWEB) , ... August 31, 2015 , ... ... health insurance, announced today their new “ InstantQuote ” tool, which summarizes all ... and easy-to-understand format. The technology tool is designed to help India Network members ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... postnatal fitness classes. , Starting September 1st they are offering pre ... Mom Bod" and "Healthy Body, Healthy Baby." , More information can be found ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award winning documentary “Alive ... “Alive Inside” shadows a social worker who advocates for the use of music therapy ... bringing music to residents in health care centers who may have lost a spark ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2
... developed by scientists at The Wistar Institute in Philadelphia ... globe through the catalog collection at the Coriell Institute ... collaboration means that scientists at a variety of research ... use in the development of vaccines and treatments for ...
... Medical Simulation Corporation (MSC),will present a ... at the SCAI/ACC national conference in,Chicago, Illinois, ... place on,Monday, March 31 at 1:30 p.m. ... The presentation represents a milestone in simulation ...
... Calif., March 25 Evalve, Inc., the leader,in the ... announced today CE Mark approval for its MitraClip(R) system. ... a,non-surgical option for patients suffering from the effects of ... of heart valve insufficiency in the United,States and the ...
... and Others Among First to Carry New Package, ... of Dog,On It! fortified juice beverage for kids, announced ... product line to five all natural,fruit-filled beverages. Shaw,s, ShopRite ... On It!, will be among a host of leading,retailers ...
... John McCain understands how to address the,challenges facing ... WASHINGTON, March 25 John McCain claims he,delivers ... speech today in,Los Angeles, the Republican candidate will ... his previous health care proposals show that,he doesn,t. ...
... or shortsightedness reveals that people who wear glasses are ... busted the myth that people who wear glasses are ... more likely to be agreeable and open, rather than ... University of Melbournes Centre for Eye Research Australia. , ...
Cached Medicine News:Health News:The Wistar Institute collaborates with the Coriell Institute to distribute cell lines 2Health News:Medical Simulation Corporation to Present Comprehensive Cardiac Patient Scenario at the Society for Cardiovascular Angiography and Interventions (SCAI) and American College of Cardiology (ACC) Conference 2Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 2Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 3Health News:Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System 4Health News:White Hat Brands Takes Dog On It! Fortified Juice Beverage for Kids to New Heights 2Health News:DNC McCain Myth Buster: John McCain and Health Care 2Health News:Mythbusted -- people who wear glasses aren't geeks 2
... The Sound Pro Combination ... table solution, combining the ... the Ultra Pro and ... ideal for OB/GYN, general ...
...
... primers and a FAM-labeled probe that is designed ... mecA gene. In addition, this ASR contains primers, ... internal control sequence. This ASR requires an instrument ... dyes such as the Cepheid SmartCycler System. The ...
... Device features the ability to use a ... and a pre-loaded nitinol filter with a ... a fully rapid exchange system, the SpideRX ... indicated applications:, Carotid Indication - ,The SpideRX ...
Medicine Products: